BioWorld Asia

July 2, 2008

EU Drug Development Slowdown Due to Biotech Complexity?

BRUSSELS, Belgium - There is a slowdown in the volume of useful new drugs on the European market, and biotech is in part to blame, according to the leading European pharmaceutical industry association. (BioWorld International) Read More

Alizyme, Norgine Team Up in $67M Marketing Deal

Blood Vessel Growth Blocker Could Be Used to Starve Tumors

Short of Money and Time, Ardana Biosciences Dies

Patent Infringement Claim Filed Against Oxford Biomedica

Oxford Profs Found Celleron to Scope Tumor Sensitivity

Immutep Reports Positive Results from LAG-3 Immunotherapy

Ascenion Adds Protectimmun to its Investment Portfolio

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 16, 2026.

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 10, 2026

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...